Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with…
Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that…
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is…
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta…
Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment Imperative Care, a medical technology company focused on advancing treatments for patients suffering…
Sutter Health Expands Use of Wearable Ultrasound Tech Across Additional Bay Area Hospitals to Advance Sepsis Care Sutter Health is expanding the use of FloPatch, the first wireless, wearable Doppler…
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector…
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment…
ImmuVia Selects Quantori’s Q-Scientist Platform to Accelerate Development of First-in-Class Cancer Therapy ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, today announced that it has selected Quantori, a…
Antiva Biosciences Presents Data from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection at SGO 2026 Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for…
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor…
Vetter Strengthens its Global Clinical Manufacturing Network with Strategic Site Enhancements Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announced significant progress in the continued expansion of its…